Option chain shows key data for Orchestra BioMed Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Orchestra BioMed Hldgs.

Orchestra BioMed Hldgs (NASDAQ:OBIO) Stock, Option Chain

Orchestra BioMed Hldgs

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Analysts Pick 4 Stocks Poised for Growth, Including Tech Giants Microsoft And Meta

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CRVS

KOPN

NWFL

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Biotech

Earnings

General

ALKS

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) shares ended the last trading session 7.3% higher at $6.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock&#39;s 12.8% gain over the past four weeks.

Orchestra BioMed Holdings, Inc. Stock Jumps 7.3%: Will It Continue to Soar?

Short Ideas

Health Care

Small Cap

CRNX

NXGN

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Top 4 Health Care Stocks That Should Keep You Up At Night

Orchestra BioMed Holdings Inc

Management

Press Releases

Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in Jefferies London Healthcare Conference

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Orchestra BioMed to Present at Upcoming Investor Conferences

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CVRx

Alpha Tau Medical

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Orchestra BioMed Hldgs

Orchestra BioMed Hldgs (OBIO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga